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Age-related Macular Degeneration (AMD) is the leading cause of visual impairment and blindness in the
elderly in developed countries. Neovascular/exudative (wet) AMD is the aggressive form of AMD and can
involve choroidal neovascularization and vascular leakage. Anti-vascular endothelial growth factor (anti-
VEGF) medications have signiﬁcantly improved treatment of wet-AMD. However, only approximately
40% of patients obtain full beneﬁt from anti-VEGF therapy and the medications are given by intravitreal
injection. Axitinib, a small molecule multi-receptor tyrosine kinase inhibitor used for the treatment of
advanced renal cell carcinoma, is taken orally and inhibits VEGF activity by blocking VEGF receptors.
Axitinib also has the advantage of blocking platelet derived growth factor (PDGF) receptors which play a
role in neovascularization. Using in vitro human retinal microvascular endothelial cells (HRMVECs),
human brain vascular pericytes (HBVRs), 3D co-culture vessel sprout assay, and in vivo laser induced rat
choroidal neovascularization (CNV) models, the effect of axitinib on neovascularization was evaluated.
Axitinib inhibited neovascularization better than anti-VEGF and/or anti-hPDGF-B mAb in the in vitro
models demonstrating that combined inhibition of both VEGF and PDGF pathways may be synergistic in
treating wet-AMD. Additionally, axitinib showed good efﬁcacy at a low dose (0.875 mg/day) in laser-
induced CNV model in rats. In conclusion our data shows that axitinib, an inhibitor of VEGF and
PDGF-B pathways may be useful in ameliorating wet-AMD therapy.
© 2016 PFIZER INC. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Age-relatedMacular Degeneration (AMD) is the leading cause of
visual impairment and blindness in the elderly in developed
countries (Ambati and Fowler, 2012; Javitt et al., 2003; Tolentino,
2009). There are two forms of AMD: dry/atrophic AMD and neo-
vascular/exudative (wet) AMD. Dry-AMD affects ~85e90% of AMD
patients (Ambati and Fowler, 2012). The hallmark of dry-AMD is theology (WCM), Pﬁzer Global
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td. This is an open access article uaccumulation of drusen and debris in the extracellular space under
the retina. Dry-AMD which is the early form can progress to wet-
AMD. Wet-AMD affects ~10e15% of AMD patients and is charac-
terized by choroidal neovascularization (CNV) in which new
immature blood vessels are formed in the choroid and proliferate
towards the outer retina, resulting in inﬂammation, vascular
leakage, retinal edema and visual loss (Ambati and Fowler, 2012;
Jager et al., 2008; Zhang et al., 2012).
Neovascularization or angiogenesis involves formation of new
blood vessels from mature blood vessels. This is a multi-step pro-
cess involving proliferation and migration of endothelial cells and
pericytes. Neovascularization is orchestrated by a variety of growth
factors including vascular endothelial growth factor (VEGF), basic-
ﬁbroblast growth factor (bFGF) and platelet derived growthnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Dorrell et al., 2007a). Anti-angiogenic drugs targeting VEGF such
as Avastin®, Lucentis® and Eylea® (Semeraro et al., 2013; Zhang
et al., 2012) are efﬁcacious for treating wet-AMD and other
retinal vascular pathologies in patients (Ambati and Fowler, 2012;
Tolentino, 2009). Although intravitreal injections of anti-VEGF
therapy have signiﬁcant therapeutic beneﬁt, in some patients vi-
sual acuity does not improve or stabilize and some patients become
refractory to the therapy over time (Forooghian et al., 2009;
Semeraro et al., 2013). As a consequence, new medications alone
or in combination with anti-VEGF therapy are being evaluated
(Dorrell et al., 2007b; Jo et al., 2006; Mabry et al., 2010a). Pericytes
which are regulated through PDGF-B signaling also play an
important role in angiogenesis, vascular maturation, stabilization
and also resistance to anti-VEGF therapies (Bagley et al., 2005;
Benjamin et al., 1998; Jo et al., 2006; Mabry et al., 2010b). Dual
targeting of VEGF and PDGF-B signaling pathways have shown
synergistic inhibition of angiogenesis in tumor and ocular neo-
vascularization models (Bagley et al., 2005; Jo et al., 2006; Mabry
et al., 2010a; Tolentino, 2009) compared to anti-VEGF mono-
therapy (Zhang et al., 2012). Small molecule kinase inhibitors that
target multiple growth factor receptors have been assessed as anti-
angiogenic agents in oncology and ocular disease models (Chung
et al., 2009; Doukas et al., 2008; Du et al., 2013; Honda et al.,
2011; Kang et al., 2013b; Takahashi et al., 2006; Yang et al., 2009).
Axitinib, a multi-receptor tyrosine kinase inhibitor has potent
inhibitory effects on VEGFR2, PDGFR-b and KIT receptors. The IC-50
values for VEGFR2, PDGFR-b and KIT were 20 pM, 1.6 nM and
1.7 nM, respectively by receptor phosphorylation assays (Hu-Lowe
et al., 2008). The efﬁcacy of axitinib in tumor models is thought to
be due to inhibition of tumor angiogenesis (Hu-Lowe et al., 2008;
Lu et al., 2015). Pre-clinical studies in various tumor models
showed that axitinib (30 mg/kg, twice daily) resulted in 70% tumor
growth inhibition (Hu-Lowe et al., 2008). This concentration
maintained the efﬁcacious plasma concentration (Ceff) for ~12 h
with good target inhibition. Currently axitinib (5 mg, twice daily) is
approved for use in advanced human renal cell carcinoma. Most
common side effects observed at this dose was hypertension (16%),
diarrhea (11%) and fatigue (11%) (Gunnarsson et al., 2015). We hy-
pothesize that axitinib can inhibit the retinal and choroidal
angiogenesis by blocking both VEGFR and PDGFR-b receptors. In
this study we evaluated the efﬁcacy of axitinib using in vitro and
in vivo models of retinal and choroidal neovascularization.
In order to evaluate efﬁcacy of axitinib on retinal angiogenesis
in vitro, following primary cells of human origin were used: human
retinal microvascular endothelial cells (HRMVECs) (CSC systems,
Kirkland, WA), human brain vascular pericytes (HBVPs) (ScienCell
Research Laboratories, Carlsbad, CA) and human mesenchymal
stem cells (hMSCs) (Lonza, Hopkinton, MA). Cells between passage-
3 to passage-8 were used in these studies. Both HRMVECs and
HBVPs had no signiﬁcant proliferation under serum free conditions
(data not shown). HRMVECs showed a dose dependent proliferative
response to human VEGF-165 (hVEGF-165), whereas human PDGF-
BB (hPDGF-BB) had no proliferative effect on these cells (data not
shown); however, HBVP showed a dose dependent proliferative
response to hPDGF-BB, whereas hVEGF-165 had no proliferative
effect on these cells (data not shown). These experiments helped us
determine 50 ng/ml of growth factor in serum free media as an
appropriate condition to evaluate anti-proliferative effects of test
compounds.
The IC-50 values of anti-hVEGFA monoclonal antibody (mAb) (a
mAb similar to Avastin®), anti-hPDGF-B mAb and axitinib (all
agents prepared within Pﬁzer Inc.) compounds were assessed. Cells
in the log phase of growth were plated at 5  103 (HRMVEC) and
2.5  103 (HBVP) cells/well on a 96 well ﬂat bottom plate andincubated overnight. Then, the plates were washed with serum-
free media and incubated with serum-free media containing
either hVEGF-165 or hPDGF-BB (R & D Systems, Minneapolis, MN)
at 50 ng/ml concentration. Serial dilutions of the compounds to be
tested were added in triplicate and incubated for 72 h at 37 C, in a
5% CO2 incubator. Viability and proliferation of the cells was
quantiﬁed with a WST-1 Cell Proliferation assay (absorbance @
450 nm) (Roche Applied Sciences, Indianapolis, IN) (Chen et al.,
2015; Zhang et al., 2015). The effect of test compounds were
compared to the proliferation of cells observed at control condi-
tions (serum-free media containing 50 ng/ml of hVEGF-165 or
hPDGF-BB). The IC-50 values were determined by non-linear
regression analysis using Graph Pad Prizm software (La Jolla, CA).
These experiments were repeated at least twice. Fig. 1A and B
shows the doseeresponse curves of anti-hVEGFA mAb, anti-
hPDGF-B mAb and axitinib on HRMVECs and HBVPs. There was a
dose dependent inhibition of HRMVEC proliferation with IC-50s of
594 pM and 3.72 pM by anti-hVEGFA mAb and axitinib, respec-
tively. Anti-hPDGF-B mAb did not have a signiﬁcant effect on the
proliferation of HRMVECs. In contrast, both anti-hPDGF-B mAb and
axitinib dose dependently inhibited the proliferation of HBVPs with
IC-50s of 621 pM and 1.79 nM, respectively, but anti-hVEGF mAb
did not have any signiﬁcant effect. These results demonstrated that
axitinib inhibits both VEGFR and PDGFR-b mediated angiogenic
pathways, albeit with different potency.
Formation of fully differentiated functional blood vessels de-
pends on intimate cellecell interaction between sprouting endo-
thelial cells, pericytes and/or their progenitor mesenchymal cells.
Sprouting endothelial cells secrete PDGF-BB which helps prolifer-
ation, differentiation and migration of pericytes to the newly
formed endothelial plexus (Benjamin et al., 1998; Darland and
D'Amore, 2001). To evaluate co-regulation of retinal endothelial
cell and pericyte differentiation, proliferation and new vessel for-
mation, a 3D co-culture sprouting assay (Ding et al., 2004; Hirschi
and D'Amore, 1997; Mabry et al., 2010a) was performed.
HRMVECs were used to mimic the retinal microenvironment.
HRMVECs (5 106 cells in EGM2 completemedia) weremixedwith
swollen cytodex-3 micro carrier beads (5000 beads) in ﬂow
cytometry tubes. The beads were coated with cells by incubating in
a 37 C incubator for 4 h, accompanied by gentle re-suspension
every 15 min. Then the beads and HRMVECs were transferred to
a T25 ﬂask with 5 ml EGM2 complete media and incubated over-
night at 37 C. On the second day of the experiment, the HRMVEC-
coated beads (50 beads/well) were embedded within a ﬁbrin gel in
a 24 well plate. Brieﬂy, human ﬁbrinogen (5 mg/ml) in EGM2
complete media with 0.15 U/ml aprotinin was sterile ﬁltered and
HRMVEC-coated beads were suspended. Human mesenchymal
cells (hMSCs) at ~4  104 per well were suspended in the above
ﬁbrinogen media containing HRMVEC coated beads. Thrombin
(25 ml of 50 U/ml) was pipetted to the center of each well and 500 ml
of ﬁbrinogen þ hMSC þ HRMVEC-bead suspension was added and
gently mixed. After initial incubation at room temperature for
5 min, the plate was incubated for 1 h at 37 C. Later 1 ml EGM2
complete media was added on top of the gel and incubated for an
additional hour at 37 C. The media on top of the gel was aspirated
and 1 ml of 1:1 mixture of EGM2 complete and D551 conditioned
media supplemented with 2 ng/ml hHGF (hereafter mentioned as
co-culture media) was added. The media was changed every other
day with 1 ml of co-culture media for a week. Starting on day 8, the
test compounds (anti-hVEGFmAb, anti-hPDGF-BmAb and axitinib)
were added with fresh co-culture media. This mixturewas replaced
every other day until day 15. On day 15 the cells were ﬁxed with 4%
paraformaldehyde for 16 h at 4 C. Each well was washed with PBS-
T and incubated with a blocking reagent (10% normal goat serum,
5% BSA, 0.2% Triton X-100 in PBS) for 2 h at room temperature. The
Fig. 1. In vitro assays show the superiority of Axitinib compared to anti-VEGF or anti-PDGF-B antibody. (A) HRMVEC and HBVP proliferation assays show that Axitinib inhibits
the proliferation. Axitinib has better sensitivity on HRMVEC compared to HBVP. (B) HRMVEC and HBVP proliferation assays show that anti-hVEGF mAb and anti-hPDGF-B mAb
inhibits the proliferation at similar potency. (C) Immunohistochemistry of the Co-culture assay. CD31 was used as an endothelial cell marker; a-SMA was used as a pericyte marker
while DAPI was the nucleus marker. The overlay images show (4 and 20) the co-localization of endothelial cells an pericytes depicting the cellecell interactions. (D) Schematic
images show the effects of anti-hVEGF mAb, anti-hPDGF-B mAb, its combination and axitinib in the co-culture assay. The sprouts in green are endothelial cells and sprouts in red are
pericytes had similar architecture. (E) Quantitation of the angiogenic sprouts from co-culture assay show superiority of axitinib compared to other treatments. * in black e vs
Vehicle; * in blue e vs anti-hVEGF mAb; * in red e vs Combo of anti-VEGF and anti-PDGF-B mAb. Statistical comparison was performed by Student's t-test. * ¼ p < 0.05;
** ¼ p < 0.005; *** ¼ p < 0.0005.
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Table 1
Fluorescence angiography scoring system.
Score Deﬁnition
0 No leakage
1 Lesions with ﬂuorescence intensity < neighboring major artery or vein
2 Lesions with ﬂuorescence intensity ¼ neighboring major artery or vein
3 Lesions with ﬂuorescence intensity > neighboring major artery or vein
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human CD31, Abcam, Cambridge, MA; Mouse anti-human a-
smooth muscle actin conjugated to Cy3, Sigma, Saint Louis, MI) and
incubated for 48 h at 4 C. Later the wells were washed with PBS-T
and incubated with secondary antibody (Goat anti-rabbit IgG-Alexa
Flour 488) and DAPI (Life Technologies Corporation, Grand Island,
NY) in the dark for 2 h at room temperature. The wells were rinsed
with PBS-T and imaged by ﬂuorescence microscopy. To represent
the entire well, 4e6 areas/beads per well were imaged at 4
magniﬁcation. The resulting images (in TIFF format) were con-
verted to grayscale image and loaded on to the Image-Pro Plus
software (Media Cybernetics Inc, Rockville, MD). Automatic quan-
titation of tube length was performed using Angiogenesis macro in
the Image-Pro Plus software. For each treatment the data is a
representative of 4e15 sprouts from 2 separate wells. Student's t-
test was performed for statistical comparison between groups.
Immuno-histochemical labeling of the vascular sprouts after the
15 day assay is represented in Fig. 1C. Endothelial cells were labeled
with CD31 marker, pericytes with aSMA and the nucleus with
DAPI. An overlay of endothelial cells and pericytes was observed at
20 magniﬁcations at most locations of the sprouts suggesting
interdependent growth and similar vascular architecture (Fig. 1C).
Fig. 1D shows the representative images of pseudo colored vascular
sprouts with endothelial cells (green), pericytes (red) and its
overlay (yellow). The quantiﬁcation of CD31 labeled images is
represented in Fig. 1E. Anti-hVEGF mAb showed a dose dependent
inhibition of the angiogenic sprouts with ~6% and 32% inhibition at
0.5 nM and 5 nM concentration, respectively (Fig. 1D and E).
Although anti-hPDGF-B mAb at 5 nM showed inhibition of angio-
genic sprouts, it was statistically not signiﬁcant compared to the
vehicle. Interestingly, a combination of anti-hVEGF and anti-
hPDGF-B mAbs at 5 nM concentration synergistically (~53%)
inhibited formation of angiogenic sprouts. Axitinib at 1 nM and
10 nM concentration inhibited ~62% and 81% of angiogenic sprouts
respectively (Fig. 1D and E). This data conﬁrms that axitinib, which
inhibits both VEGFR and PDGFR-b, is superior to either anti-hVEGF
and/or anti-hPDGF-B for inhibiting endothelial and pericyte
mediated vessel formation.
It was hypothesized that lower doses of axitinib (i.e., <5 mg
twice a day approved for use in advanced human renal cell
carcinoma) may be able to elicit efﬁcacy while minimizing the
tyrosine kinase inhibitor class-related adverse events resulting
from systemic concentrations of the drug. To evaluate the effects of
low-dose axitinib, a laser induced rat CNV model was used
(Edelman and Castro, 2000). All animal experiments were carried
out under protocols approved by the Institutional Animal Care and
Use Committee (IACUC). Animals were housed under standard
12:12 light:dark cycle in ventilated racks at a room temperature of
72 F with a relative humidity (RH) between 30 and 70%. Male
Brown Norway (BN) rats weighing ~250 g were obtained from
Charles River Laboratories, Inc. (Wilmington, MA). The rats were
anesthetized with a 1.5 ml/kg intraperitoneal injection of a 1:1
mixture of ketamine HCl (100 mg/ml) dexmedetomidine HCl
(0.5 mg/ml). Their eyes were topically anesthetized with 0.5%
proparacaine eye drops and their pupils were dilated with 1% tro-
picamide and 10% phenylephrine HCl topical eye drops for laser
photocoagulation and ﬂuorescein angiography. The rats were
positioned at a slit lamp with an argon green laser delivery system.
Their funduswas visualized using amicroscope cover slip with 0.3%
hydroxypropylmethylcellulose as an optical coupling agent. Four to
six laser photocoagulation spots were created in each eye between
major retinal vessels (532 nm wavelength; 110 mW power; 0.1 s
duration; and 50 mm spot size; Eyelite 532 nm Ophthalmic Laser;
Alcon, Fort Worth, TX). Disruption of Bruch's membrane was
conﬁrmed by central bubble formation. Only rats with 4 goodlesions in each eye were included in the study. Following laser
treatments of both eyes, the animals were randomized into two
groups. Each group received axitinib (n ¼ 5) or vehicle (n ¼ 4) 7
days after the laser photocoagulation to follow the interventional
treatment paradigm.
Previous pre-clinical and clinical studies showed that axitinib
has a very short plasma half-life (~2.5e6.1 h) when dosed orally
(Chen et al., 2013; Hu-Lowe et al., 2008; Rixe et al., 2007). Conse-
quently axitinib or its vehicle was administered as a sustained
continuous infusion using an osmotic mini pump. Axitinib was
formulated in a vehicle composed of 45%DMSO: 40%PEG400: 15%
Cremophor ELP mixture and loaded into an Alzet Osmotic Pump -
Model 2ML1 (Durect Corporation, Cupertino, CA) according to the
manufacturer's instructions. The concentration of axitinib was
adjusted to obtain a dose of 0.875 mg/day. For Alzet pump im-
plantation, animals were anesthetized using isoﬂurane and the
surgical site was prepared by clipping the hair followed with
ChloraPrep® (San Diego, CA) scrub. Bupivicaine (0.5 mg/kg) was
administered subcutaneously at the incision site and an incision
was made in the skin. The dosing pump was inserted completely
into the pocket with the ﬂow moderator facing away from the
incision site and the skin was closed with stainless steel staples.
Ketoprofen (5 mg/kg, once daily) was administered 30 min prior to
surgery and the next day as an analgesic. At the end of the study, the
pumps were removed and evaluated for the release of the drug.
Antibodies (anti-hVEGF and anti-hPDGF-B) were not evaluated in
this model as they were not rodent reactive.
The effects of axitinib in rat CNV model were evaluated by
ﬂuorescein angiography (FA) and isolectin B4 staining. FA is a
technique used to assess vascular leakage from the CNV lesions
(Edelman and Castro, 2000), whereas isolectin B4 staining is a
technique used to evaluate neovascularization (Du et al., 2013). FA
was performed on day 14 post-laser photocoagulation as described
previously (Edelman and Castro, 2000). Sodium ﬂuorescein
(100 mg/kg body weight; AK-Flour 10%, Akron Pharmaceuticals,
Lake Forest, IL) was administered intraperitoneally and FA images
were captured at 5e10 min after injection. Scoring (0e3 scale) was
performed as described in Table 1. The relative number of lesions
(as percentage) with FA scores 1e3 is represented in Fig. 2A
whereas the mean score of the lesions is represented in Fig. 2B.
After FA, the rats were euthanized and eyes were collected for
microscopy and image analysis of the choroidal whole mounts.
Brieﬂy, eyes were enucleated and stored in 10% formalin for 2 h
prior to hemi-section and removal of the lens and neural retina. The
resulting eyecups were stained with FITC-conjugated isolectin B4
(Sigma; St. Louis, MO). Then 4e6 radial cuts were made in the eye
cups to obtain a ﬂat mount for mounting on a microscope slide
(RPE-side facing up) using gel mount media (Aqua-Poly/Mount;
Polysciences Inc,Warrington, PA) and a cover slip. CNV lesions were
examined using the 10 objective lens of an epiﬂuorescent mi-
croscope (Nikon Eclipse; Nikon, Japan) and images were captured
using a digital camera attached to the microscope. Representative
images are shown in Fig. 2C. The area of CNV lesion was quantiﬁed
by software Image-Pro Plus 7.0 (MediaCybernetics, Rockville, MD)
using a custom designed angiogenesis algorithm. For statistical
comparison the mean CNV areas of axitinib group was normalized
Fig. 2. Axitinib inhibits the angiogenesis and vascular leakage in in vivo rat choroidal neovascularization (CNV) model. (A) Fluorescein angiography (FA) shows that axitinib
reduces the percentage of lesions with a score equal to 2 (B) and the mean score of the FA lesions in the axitinib treated group is signiﬁcantly less than the vehicle treated group. (C)
Staining of choroidal whole mounts with isolectin B4, a marker of vasculature/endothelial cells show reduction of CNV lesion size. (D) Quantitation of the CNV area using Image-Pro
Plus software show statistically signiﬁcant inhibition of the CNV area in the axitinib treated group compared to the vehicle treated group. Number of lesions scored for FA and CNV
was 20e28/group. Statistical comparison was performed by Student's t-test. * ¼ p < 0.01; ** ¼ p < 0.005.
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FA scoring (as per Table 1), on day 14 post laser photocoagula-
tion showed that ~75% of lesions in the vehicle group had scores
equal to 2 (Fig. 2A). The axitinib treated group had maximum le-
sions with score 1 (~58%) followed by score 2 (~28%) suggesting a
dramatic decrease in the score 2 lesions (Fig. 2A). The mean FAscore for the vehicle treated eyes was 2.05 (±0.11, SEM)whereas the
axitinib treated eyes had a signiﬁcantly decreased mean FA score of
1.57 (±0.14, SEM) (Fig. 2B) suggesting a decrease in vascular
leakage. At the end of the study the eye cups were stained with
isolectin B4 and ﬂat mounted for microscopy. A signiﬁcant reduc-
tion (~33% ± 6.7, SEM) in the CNV lesion area was observed in the
A. Giddabasappa et al. / Experimental Eye Research 145 (2016) 373e379378microscopic images compared to the vehicle treated group (Fig. 2C
and D). These results demonstrated that low dose axitinib was
effective in reducing vascular leakage and neovascularization in
laser induced CNV rat model.
Anti-VEGF therapy (Lucentis® and Eylea®) has become the
standard of care for treating wet-AMD patients (Semeraro et al.,
2013; Tolentino, 2009; Zhang et al., 2012). Although this
approach has been beneﬁcial to many patients, a signiﬁcant num-
ber of patients do not improve or respond to anti-VEGF therapy
because of acquired resistance and/or emergence of alternative
pathways for angiogenesis (Jo et al., 2006; Tranos et al., 2013).
Angiogenesis involves interaction between multiple cell types.
VEGF signaling primarily regulates the proliferation, survival and
migration of endothelial cells where as PDGF-BB signaling regulates
pericytes. These two cell types interact extensively during angio-
genesis (Bagley et al., 2005; Benjamin et al., 1998; Hu-Lowe et al.,
2008). Thus inhibiting both cell types may overcome the refracto-
riness to anti-VEGF monotherapy. There have been a few pre-
clinical and clinical studies showing that the combination of anti-
VEGF with anti-PDGFB therapy has additional therapeutic beneﬁt
(Jo et al., 2006; Stewart, 2012). The present study, using in vitro
proliferation assays with HRMVECs and HBVPs demonstrated that
anti-VEGF treatment only inhibits endothelial cell proliferation and
anti-PDGF-B treatment only inhibits pericyte proliferation, whereas
axitinib can inhibit both endothelial and pericyte proliferation.
Additionally, axitinib has a 2 log higher sensitivity to VEGFR
compared to anti-VEGF mAb, whereas the sensitivity of axitinib to
the PDGFR-b was similar to the effect observed with anti-PDGF-B
mAb. The 3D sprouting assay is an in vitro tool to measure the
interaction between endothelial cells and pericyte during the for-
mation of functional vessels. Our results showed that anti-VEGF
and anti-PDGF-B mAbs moderately inhibit sprout formation;
however, the combination of both anti-VEGF and anti-PDGF-B
mAbs and low concentrations of axitinib alone signiﬁcantly
reduced 3D sprout formation. This implies that inhibiting both
VEGF and PDGF-B will synergistically reduce neovascularization.
Finally, the tumor growth inhibition studies had demonstrated
that 70% anti-tumor efﬁcacy was observed at ~30 mg/kg, twice
daily administration (Hu-Lowe et al., 2008). In this study, we show
continuous administration of axitinib at a lower dose (0.875 mg/
day) for 7 days signiﬁcantly inhibited vascular leakage and neo-
vascularization in rat CNVmodel. Consistent with our ﬁndings, oral
dosing of axitinib at 5 mg/kg inhibited laser induced CNV lesions in
a mouse model (Kang et al., 2013a). Additionally, it has been shown
that co-administration of axitinibwith an anti-VEGFmAb increased
the anti-angiogenesis effect of the anti-VEGF mAb (Hu-Lowe et al.,
2008). A lower dose of axitinib may reduce its known side effects
(Gunnarsson et al., 2015) while still effectively decreasing choroidal
neovascularization in wet-AMD patients. Overall, our results show
that axitinib, a small molecule inhibitor of VEGF and PDGF-B
pathways may be useful in wet-AMD therapy. Future studies eval-
uating the safety of chronic low-dose axitinib and a sustained
release ophthalmic delivery platform may be warranted for its
therapeutic utility.
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